Liquidia (NASDAQ:LQDA) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Liquidia (NASDAQ:LQDA) in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a $29.00 target price on the stock.

Several other analysts have also recently commented on the stock. Bank of America reduced their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Scotiabank initiated coverage on Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price for the company. BTIG Research decreased their price target on Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, August 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded down $0.04 during trading on Thursday, reaching $9.98. The company had a trading volume of 365,846 shares, compared to its average volume of 978,632. Liquidia has a fifty-two week low of $6.10 and a fifty-two week high of $16.99. The stock’s fifty day moving average price is $10.48 and its 200 day moving average price is $11.52. The firm has a market capitalization of $766.36 million, a price-to-earnings ratio of -6.15 and a beta of 0.21.

Insider Transactions at Liquidia

In other news, Director Caligan Partners Lp acquired 150,000 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were bought at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This trade represents a 2.19 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 2,526 shares of Liquidia stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the sale, the insider now owns 204,857 shares in the company, valued at $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,551 shares of company stock valued at $236,021 over the last three months. 30.10% of the stock is currently owned by insiders.

Institutional Trading of Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC acquired a new position in Liquidia in the second quarter worth about $27,000. Hilltop National Bank acquired a new position in Liquidia in the second quarter worth $33,000. Clear Harbor Asset Management LLC bought a new stake in shares of Liquidia during the 3rd quarter valued at about $100,000. Signaturefd LLC lifted its holdings in Liquidia by 38,400.0% in the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after acquiring an additional 9,984 shares during the last quarter. Finally, Ballentine Partners LLC acquired a new position in Liquidia during the 3rd quarter valued at approximately $110,000. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).